West Pharmaceutical Services, Inc.
Analysis
West has flipped from a recovery story into an acceleration story: guidance has been raised twice in three calls, and the growth now comes from upgrading ordinary stoppers and seals rather than from obesity drugs alone.How much of the acceleration is upgrades versus new drug launches?
- The growth is no longer about obesity drugs.
Non-GLP-1 high-value components grew in the high teens and drove most of the quarter's outperformance, after being roughly flat in 2025. That business now supplies most of the year's growth, so West no longer rests on obesity drugs.How fast is West converting its Annex 1 project pipeline?
- Guidance has been raised twice and still looks beatable.
Guidance has been raised twice in three quarters, now to 10-11% organic growth, and management calls the plan prudent. Profit has beaten the Street five quarters running, so the ceiling keeps rising behind the numbers it reports.How much of the raised 2026 outlook comes from price alone?
- Profit is outrunning the cash the business collects.
Revenue rose 17% in the first half, yet cash collected from customers fell and West spent more on buybacks than the business generated. Management blames the cyber incident and says it unwinds, so watch whether that cash returns.
- High-value components outside GLP-1 keep growing in the high teens. Most extra sales then come from many drugs instead of one, so a single customer's slowdown cannot stall the year.
- Annex 1 upgrades keep converting at roughly 200 basis points a year. These are the same stoppers and seals sold at a higher price, so sales and margins rise without extra volume.
- Throughput gains keep coming without building new plants. West grows on equipment it already owns, so more of each extra dollar of sales survives to the bottom line.
- Orals win the obesity market faster than West assumes. Pills use far fewer of West's parts than injections, so the market West relies on most would grow slower than planned.
- Demand keeps outrunning what West can produce. Customers wait for parts, or qualify a second supplier elsewhere, and West itself says it is still catching up.
- The second half carries one-offs the first half did not. A lost contract and pricier oil land before the new Dublin work pays off, so growth looks slower than the business is.
| Politician | Transaction | Amount | Traded | Filed |
|---|---|---|---|---|
Donald Trump Republican · Executive | Purchase | ≥$250K | Feb 10 | May 13 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Jun 2 | Jul 6 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | May 27 | Jun 9 |
Ro Khanna Democratic · House · CA-17 | Sale | ≥$1K | Feb 5 | Mar 9 |
Ro Khanna Democratic · House · CA-17 | Purchase | ≥$1K | Jan 29 | Feb 6 |
Congressional trading data provided by QuiverQuant
How West Pharmaceutical Services turned $3.1B of revenue into $584.9M of operating income.
| Revenue | ||
|---|---|---|
| Proprietary Products | $2.5B | ▲ 6.75% YoY |
| Contract Manufactured Products | $582.0M | ▲ 4.17% YoY |
| Total revenue | $3.1B | |
| Gross profit | $1.1B | 35.9% |
| Operating income | $584.9M | 19.0% |